Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma

doi:10.1097/CJI.0000000000000521

	Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
	Song, Peng 1; Li, Yuan 2; Zhang, Moyan 2; Lyu, Baihan 3; Cui, Yong 1; Gao, Shugeng 2
通讯作者	Gao, Shugeng(shugenggao@126.com)
摘要	With the development of immune checkpoints inhibitors (ICIs), immunotherapy has recently taken center stage in cancer treatment. Dendritic cells exert complicated and important functions in antitumor immunity. This study aims to construct a novel dendritic cell marker gene signature (DCMGS) to predict the prognosis and immunotherapy response of lung adenocarcinoma (LUAD). DC marker genes in LUAD were identified by analysis of single-cell RNA sequencing data. 6 genes (G0S2, KLF4, ALDH2, IER3, TXN, CD69) were screened as the most prognosis-related genes for constructing DCMGS on a training cohort from TCGA data set. Patients were divided into high-risk and low-risk groups by DCMGS risk score based on overall survival time. Then, the predictive ability of the risk model was validated in 6 independent cohorts. DCMGS was verified to be an independent prognostic factor in multivariate analysis. Furthermore, we performed pathway enrichment analysis to explore possible biological mechanisms of the powerful predictive ability of DCMGS, and immune cell infiltration landscape and inflammatory activities were exhibited to reflect the immune profile. Notably, we bridged DCMGS with expression of immune checkpoints and TCR/BCR repertoire diversity that can inflect immunotherapy response. Finally, the predictive ability of DCMGS in immunotherapy response was also validated by 2 cohorts that had received immunotherapy. As a result, the patients with lower DCMGS risk scores showed a better prognosis and immunotherapy response. In conclusion, DCMGS was suggested to be a promising prognostic indicator for LUAD and a desirable predictor for immunotherapy response.
关键词	Lung adenocarcinoma Dendritic cell mark genes Prognostic signature Immunotherapy Bioinformatics
	2025
语种	英语
DOI	10.1097/CJI.0000000000000521
发表期刊	JOURNAL OF IMMUNOTHERAPY
ISSN	1524-9557
卷号	48 期号:1 页码:6-17
收录类别	SCI
资助项目	National Key R&D Program of China[2021YFC2500900] ; Minimally invasive Surgery Research Program of China Medical Foundation[ZGYXJJH-WCWK-2023062002] ; Science and Technology Program of Tongzhou District, Beijing[KJ2023CX005]
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS关键词	T-CELL ; CANCER ; ACTIVATION ; RESISTANCE ; LANDSCAPE
WOS研究方向	Oncology ; Immunology ; Research & Experimental Medicine
WOS类目	Oncology ; Immunology ; Medicine, Research & Experimental
WOS记录号	WOS:001369598400003
资助机构	National Key R&D Program of China ; Minimally invasive Surgery Research Program of China Medical Foundation ; Science and Technology Program of Tongzhou District, Beijing
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://ir.psych.ac.cn/handle/311026/48683
专题	中国科学院行为科学重点实验室
通讯作者	Gao, Shugeng
作者单位	1.Capital Med Univ, Beijing Friendship Hosp, Dept Thorac Surg, Beijing 100050, Peoples R China 2.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept ofThorac Surg, Beijing 100050, Peoples R China 3.Chinese Acad Sci, Inst Psychol, CAS Key Lab Behav Sci, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Song, Peng,Li, Yuan,Zhang, Moyan,et al. Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma[J]. JOURNAL OF IMMUNOTHERAPY,2025,48(1):6-17.
APA	Song, Peng,Li, Yuan,Zhang, Moyan,Lyu, Baihan,Cui, Yong,&Gao, Shugeng.(2025).Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma.JOURNAL OF IMMUNOTHERAPY,48(1),6-17.
MLA	Song, Peng,et al."Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma".JOURNAL OF IMMUNOTHERAPY 48.1(2025):6-17.